Form 8-K - Current report:
SEC Accession No. 0001641172-25-015675
Filing Date
2025-06-20
Accepted
2025-06-20 06:05:36
Documents
16
Period of Report
2025-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 44460
2 EX-4.1 ex4-1.htm EX-4.1 95681
3 EX-4.2 ex4-2.htm EX-4.2 111344
4 EX-4.3 ex4-3.htm EX-4.3 109652
5 EX-10.1 ex10-1.htm EX-10.1 224600
  Complete submission text file 0001641172-25-015675.txt   874586

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE thar-20250613.xsd EX-101.SCH 3020
7 XBRL LABEL FILE thar-20250613_lab.xml EX-101.LAB 34239
8 XBRL PRESENTATION FILE thar-20250613_pre.xml EX-101.PRE 22362
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3668
Mailing Address 245 MAIN STREET SUITE 204 CHESTER NJ 07930
Business Address 1200 ROUTE 22 EAST BRIDGEWATER NJ 08807 302-743-2995
Tharimmune, Inc. (Filer) CIK: 0001861657 (see all company filings)

EIN.: 842642541 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41210 | Film No.: 251058942
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)